MGMT and glioma: (78), a national phase I/II study of MFA/TMZ combination treatment in recurrent MGMT-methylated glioblastoma (“MecMeth” EudraCT2021-000708-39) is underway in Germany to measure the concentrations of MFA within gliomas, examine the safety and practicality of a combined MFA/TMZ strategy, and may acquire first insights into the effectiveness of MFA as the first clinically viable TM-targeted medication.